The phase 3 IMpactMF study will be discontinued after an independent committee determined it was unlikely to meet its primary end point of overall survival.
|Videos|December 15, 2017
Novel Agent Active in Refractory Polycythemia Vera
Author(s)John O. Mascarenhas, MD
This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
Advertisement
In this video, John O. Mascarenhas, MD, of the Tisch Cancer Institute at Mount Sinai in New York, highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
Mascarenhas presented results of the study (
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5